Literature DB >> 25663995

Inhibition of matrix metalloproteinase-9 with low-dose doxycycline reduces acute lung injury induced by cardiopulmonary bypass.

Chengxin Zhang1, Wenhui Gong2, Haiyuan Liu3, Zhixiang Guo1, Shenglin Ge1.   

Abstract

OBJECTIVE: This study aims to demonstrate the protective effect of doxycycline, an exogenous inhibitor of matrix metalloproteinases-9 (MMP-9), in the acute lung injury induced by cardiopulmonary bypass (CPB).
METHODS: A total of 30 healthy mongrel dogs were randomly divided into three groups: Group A (CPB control group, no treatment of doxycycline), Group B (low-dose group, treated with doxycycline at 30 mg/kg) and Group C (high-dose group, doxycycline at 60 mg/kg). The alveolar-arterial oxygen difference (A-aDO2) and respiratory index (RI) were calculated, the concentration of MMP-9 in plasma was measured by ELISA. The expression levels of MMP-9 was determined by RT-PCR. The lung W/D index was calculated. The myeloperoxidase (MPO) activity of bronchoalveolar lavage fluid (BALF) was measured by colorimetry. The total protein of BALF was measured by Coomassie brilliant blue G-250. The white blood count (WBC) in the sediment of BALF was counted.
RESULTS: A-aDO2, RI, total protein, and MPO activity of BALF, WBC count in BALF sediment and W/D index in group B were significantly lower than that of control group (P < 0.05). The concentration of MMP-9 in group C decreased significantly (P < 0.05). There were no significant differences in gene expression among the three groups.
CONCLUSION: The results suggested that doxycycline protected the acute lung injury induced by CPB through reducing the concentration of MMP-9 and degradation of the cell membrane, pulmonary neutrophil infiltration and pulmonary edema.

Entities:  

Keywords:  Cardiopulmonary bypass; acute lung injury; doxycycline; lung protection; matrix metalloproteinase

Year:  2014        PMID: 25663995      PMCID: PMC4307442     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Systemic inflammatory response syndrome after cardiac operations.

Authors:  J Cremer; M Martin; H Redl; S Bahrami; C Abraham; T Graeter; A Haverich; G Schlag; H G Borst
Journal:  Ann Thorac Surg       Date:  1996-06       Impact factor: 4.330

2.  Evidence of increased matrix metalloproteinase-9 concentration in patients following cardiopulmonary bypass.

Authors:  J Steinberg; G Fink; A Picone; B Searles; H Schiller; H M Lee; G Nieman
Journal:  J Extra Corpor Technol       Date:  2001-12

3.  Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury.

Authors:  T S Gipson; N M Bless; T P Shanley; L D Crouch; M R Bleavins; E M Younkin; V Sarma; D F Gibbs; W Tefera; P C McConnell; W T Mueller; K J Johnson; P A Ward
Journal:  J Immunol       Date:  1999-03-15       Impact factor: 5.422

4.  Neutrophil-mediated secretion and activation of matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass.

Authors:  Tso-Chou Lin; Chi-Yuan Li; Chien-Sung Tsai; Chih-Hung Ku; Ching-Tang Wu; Chih-Shung Wong; Shung-Tai Ho
Journal:  Anesth Analg       Date:  2005-06       Impact factor: 5.108

5.  Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass.

Authors:  D E Carney; C J Lutz; A L Picone; L A Gatto; N S Ramamurthy; L M Golub; S R Simon; B Searles; A Paskanik; K Snyder; C Finck; H J Schiller; G F Nieman
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

Review 6.  Activation mechanisms of matrix metalloproteinases.

Authors:  H Nagase
Journal:  Biol Chem       Date:  1997 Mar-Apr       Impact factor: 3.915

7.  Matrix metalloproteinase inhibitor: differential effects on pulmonary neutrophil and monocyte sequestration following cardiopulmonary bypass.

Authors:  U G McCann; L A Gatto; B Searles; D E Carney; C J Lutz; A L Picone; H J Schiller; G F Nieman
Journal:  J Extra Corpor Technol       Date:  1999-06

Review 8.  Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass.

Authors:  G Asimakopoulos; P L Smith; C P Ratnatunga; K M Taylor
Journal:  Ann Thorac Surg       Date:  1999-09       Impact factor: 4.330

9.  Effects of MMP-9 inhibition by doxycycline on proteome of lungs in high tidal volume mechanical ventilation-induced acute lung injury.

Authors:  Adrian Doroszko; Thomas S Hurst; Dorota Polewicz; Jolanta Sawicka; Justyna Fert-Bober; David H Johnson; Grzegorz Sawicki
Journal:  Proteome Sci       Date:  2010-01-29       Impact factor: 2.480

10.  Lack of matrix metalloproteinase-9 worsens ventilator-induced lung injury.

Authors:  Guillermo M Albaiceta; Ana Gutiérrez-Fernández; Diego Parra; Aurora Astudillo; Emilio García-Prieto; Francisco Taboada; Antonio Fueyo
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-01-25       Impact factor: 5.464

View more
  7 in total

Review 1.  Possible Treatment Approaches of Sulfur Mustard-Induced Lung Disorders, Experimental and Clinical Evidence, an Updated Review.

Authors:  Mohammad Reza Khazdair; Mohammad Hossein Boskabady
Journal:  Front Med (Lausanne)       Date:  2022-04-29

2.  MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus.

Authors:  Estefania Ugarte-Berzal; Lise Boon; Erik Martens; Vasily Rybakin; Daniel Blockmans; Jennifer Vandooren; Paul Proost; Ghislain Opdenakker
Journal:  Front Immunol       Date:  2019-03-22       Impact factor: 7.561

Review 3.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 4.  Strategies for Pharmacological Organoprotection during Extracorporeal Circulation Targeting Ischemia-Reperfusion Injury.

Authors:  Aida Salameh; Stefan Dhein
Journal:  Front Pharmacol       Date:  2015-12-22       Impact factor: 5.810

5.  Anti-influenza A virus activity of rhein through regulating oxidative stress, TLR4, Akt, MAPK, and NF-κB signal pathways.

Authors:  Qian-Wen Wang; Yun Su; Jiang-Tao Sheng; Li-Ming Gu; Ying Zhao; Xiao-Xuan Chen; Cheng Chen; Wei-Zhong Li; Kang-Sheng Li; Jian-Ping Dai
Journal:  PLoS One       Date:  2018-01-31       Impact factor: 3.240

6.  ATIQCTPC targeting MMP-9: a key step to slowing primary tumor growth and inhibiting metastasis of lewis lung carcinoma in vivo.

Authors:  Yuji Wang; Xinyi Xu; Ce Song; Jianhui Wu; Xi Hu; Haimei Zhu; Xiaoyi Zhang; Yaonan Wang; Lin Gui; Ming Zhao; Shiqi Peng
Journal:  Oncotarget       Date:  2017-07-10

Review 7.  Immunomodulation by Tetracyclines in the Critically Ill: An Emerging Treatment Option?

Authors:  Andrea Sauer; Christian Putensen; Christian Bode
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.